Menagen and Pharmosa Announce In-Licensing Collaboration for Sustained-Release Inhaled Treprostinil Product in MENAT Region

Menagen exclusively licenses MENAT rights for inhaled formulation of treprostinil

Menagen exclusively licenses MENAT rights to L606, an inhaled formulation of treprostinil administered twice daily with a short-duration, next-generation nebulizer

Menagens focus is to facilitate localization and access to innovative medicines for patients in need within the MENAT region through a diversified portfolio to cover multiple unmet needs of different illnesses.